Strides Pharma gains 3% as Singapore arm acquires 100% stake in Amexel Pte

Strides Pharma shares gained 2.8 per cent on BSE, logging an intraday high at Rs 603 per share in Tuesday’s trade. The buying interest sparked after the company arm Strides Pharma Global proposed to acquire 100 per cent stake in Amexel Pte. Ltd., Singapore.

Around 10:30 AM, Strides Pharma share price was up 2.23 per cent at Rs 599.10 per share on BSE. In comparison, the BSE Sensex was up 0.43 per cent at 74,145.46. The market capitalisation of the company stood at Rs 5,521.47 crore. The 52-week high of the stock was at Rs 804.12 per share and the 52-week low was at Rs 329.76 per share.

“It is proposed to acquire 100 per cent stake in Amexel Pte. Ltd., Singapore, which will be utilised as the entity for the above business platform,” the filing read

The acquisition was proposed after Strides Pharma Global Pte. Limited, a subsidiary of the company in Singapore, proposed to create a platform that shall foster introductions, collaborations, procurement and business engagement between pharmaceutical manufacturers and suppliers of India, China, and other Southeast-Asian countries.

Strides Pharma (Strides Pharma Science Limited) is a global pharmaceutical company based in India, specializing in the development, manufacture, and distribution of generic medicines, including injectables, oral solids, and specialty products. It has a significant global presence, with operations in over 100 countries, including strong markets in the US, Europe, and Australia.

The company’s product portfolio includes anti-retrovirals, oncology drugs, antibiotics, and other therapeutic areas, with a focus on high-value injectables. Strides Pharma operates state-of-the-art manufacturing facilities across India and abroad, many of which are FDA-approved. It has made strategic acquisitions, such as the purchase of Agila Specialties, to expand its capabilities in injectables.

The company places a strong emphasis on R&D to develop complex generics and specialty drugs. Despite facing challenges in the competitive pharmaceutical sector, Strides Pharma continues to grow by diversifying its offerings and investing in emerging markets.

In the past one year, Strides Pharma shares have gained 53 per cent against Sensex’s rise of 1.4 per cent.

Related Posts

  • Pharma
  • July 24, 2025
  • 308 views
Natco Pharma shares dip over 2% after Rs 2,000-crore stake buy in South Africa’s Adcock Ingram

Natco Pharma shares slipped 2.5% to Rs 1,009 apiece on the BSE in Thursday’s trade after the company announced its plan to acquire a 35.75% stake in South Africa-based Adcock…

  • Pharma
  • July 22, 2025
  • 350 views
DGFT Extends Deadline on Application for Export of Pharma Grade Sugar

The Directorate General of Foreign Trade ( DGFT ) has notified an extension in the deadline for submitting applications for the export of Pharma Grade Sugar. This was communicated through Trade Notice…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Natco Pharma shares dip over 2% after Rs 2,000-crore stake buy in South Africa’s Adcock Ingram

Natco Pharma shares dip over 2% after Rs 2,000-crore stake buy in South Africa’s Adcock Ingram

10, 000 Km is just a Number for Intercontinental Tele Surgery by SSIMantra

10, 000 Km is just a Number for Intercontinental Tele Surgery by SSIMantra

DGFT Extends Deadline on Application for Export of Pharma Grade Sugar

DGFT Extends Deadline on Application for Export of Pharma Grade Sugar

Bihar Healthcare is poised to be embraced by Robotic Surgery Mantra

Bihar Healthcare is poised to be embraced by Robotic Surgery Mantra